Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term infliximab maintenance versus intermittent therapy in moderate to severe plaque psoriasis
2005-005367-28Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of infliximab in plaque psoriasis (2 arms), sponsored by Merck & Co. Primary endpoint: PASI75 response rate at Week 128. Started Jun 2006; status: completed.
02
Drugs
infliximab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2005-005367-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005367-28.